Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Vice President, Cell Biology, Xencor
David Szymkowski leads the immunology group as vice president of cell biology at Xencor, a clinical-stage company developing bispecific antibodies and engineered cytokines for the treatment of cancer and autoimmune diseases. Currently, 15 drug candidates engineered with Xencor’s XmAb® technology are in clinical development or are marketed by Xencor’s partners. Prior to joining Xencor in 2002, Dr. Szymkowski was a principal scientist in the respiratory group at Roche Bioscience in Palo Alto, CA. Previously, he was a virology program leader at Roche in the U.K. With over 25 years of experience at Roche and Xencor, Dr. Szymkowski has been instrumental in 10 IND submissions, has coauthored over 40 papers and reviews, is an inventor on over a dozen patents, and speaks frequently on the development of antibody therapeutics and other biologics. Dr. Szymkowski also serves on the board of directors of INmune Bio, a clinical-stage biotech that is developing therapies targeting the innate immune system to treat disease. He received his B.A. at Johns Hopkins University and his Ph.D. in molecular and cell biology from Penn State, and he completed a post-doctoral fellowship at the Imperial Cancer Research Fund (U.K.).